Introduction
Since the Food and Drug Administration [FDA] approval of infliximab for Crohn's disease [CD] in 1998, biological therapy has gradually become the preferred treatment for moderate to severe inflammatory bowel disease [IBD] . Adalimumab and certolizumab pegol, also anti-tumour necrosis-alpha [TNFα] inhibitors, were approved for moderate to severe CD in 2007 and 2008, respectively. Infliximab, adalimumab and golimumab are now approved for moderate to severe ulcerative colitis [UC] . While there is no doubt that these are effective medications for treating IBD, the efficacy of anti-TNFα therapy has been limited by primary non-response, secondary loss of response and treatment intolerance. Investigators have worked to fill this therapeutic gap, exploring therapies with different mechanisms of action. Vedolizumab [Entyvio™, Takeda Pharmaceuticals America], a humanized monoclonal antibody to the α4β7 integrin (whose ligand is mucosal addressin cell adhesion molecule-1 [MAdCAM-1], localized to the endothelial cells within the gastrointestinal tract), was approved by the FDA for moderate to severe UC and CD in May 2014.
There was great enthusiasm for vedolizumab's approval because of its gut selectivity and theoretically more favourable safety profile. The pivotal placebo-controlled trials of vedolizumab demonstrated significantly improved remission rates and CD Activity Index scores among patients with moderate to severe CD, and significantly improved clinical remission rates and Mayo scores and quality of life among patients with moderate to severe UC. 1, 2 A recent integrated safety analysis of vedolizumab underlined its favourable safety profile. 3 While neither trial found a significantly increased infectious complication rate, the studies did not specifically examine surgical outcomes, and in fact excluded patients with stomas and intestinal strictures.
There are no published data regarding vedolizumab's effect on postoperative outcomes, an important consideration in the interdisciplinary management of IBD, especially for operative timing, operative approach and need for diversion in the setting of a new anastomosis. The mechanism of vedolizumab's action, blocking leukocyte migration to the intestine, is a particular concern for surgeons, as healing of intestinal anastomoses or the mucocutaneous interface of a stoma is dependent upon the presence of leukocytes as a major component and coordinator of wound healing. [4] [5] [6] [7] Failure of appropriate intestinal healing in the postoperative period may contribute to the development of major complications, including anastomotic leaks or development of organ space surgical site infections [SSIs] . Deep space infections may be considered as a surrogate of ineffective wound healing. The risk of SSIs is an important consideration with any new immunosuppressant used perioperatively, as SSIs significantly increase patient morbidity and length of hospital stay. 8, 9 As the use of vedolizumab increases in the IBD patient population, its possible impact on postoperative recovery is critical to understand. Therefore, we sought to determine the rate of postoperative infectious complications among IBD patients who received vedolizumab within 12 weeks of a major abdominal operation as compared to patients exposed to either TNFα inhibitors or no biological therapy within 12 weeks of a major abdominal operation.
Materials and Methods
Following institutional review board approval, a retrospective chart review of the Mayo Clinic Rochester electronic medical record system between May 20, 2014 and December 31, 2015 was performed. A list of all UC and CD patients who underwent a major abdominal operation was obtained. Study patients included adults [aged 18-70 years] with UC or CD who received vedolizumab within 12 weeks of a major abdominal operation. Two separate control cohorts included those patients exposed to TNFα inhibitors within 12 weeks of a major abdominal operation and patients not exposed to any biological therapy within 12 weeks of a major abdominal operation. Patients were excluded if they did not have 30 days of follow-up after their operation or if their operation was performed at an outside hospital. Data abstracted included patient demographics, IBD subtype, smoking history, duration of vedolizumab administration, date and type of surgery, concomitant immunosuppressive medications, and postoperative infectious complications and mortality.
The primary endpoint was postoperative infectious complications, including SSIs, anastomotic leak, catheter-associated infection, urinary tract infection and respiratory tract infection, occurring within the first 30 post-operative days.
Statistical analysis
Continuous variables were expressed as mean ± SD or as median [range] . Differences in the means between subgroups were compared using the t test. Comparisons between categorical variables were analysed using the Fisher's exact test. A p value of <0.05 was considered statistically significant. Univariate and multivariable logistic regression was used to determine predictors of SSIs among all IBD patients as well as within the vedolizumab study cohort. Table 5 ]. Upon multivariate analysis, perioperative use of vedolizumab remained significantly associated with the development of SSIs whether the control group was the no biologics cohort or the TNFα group [ Table 6 ]. Interestingly, in multivariate analysis, perioperative TNFα inhibitor was not associated with the development of SSIs as compared to no biologics exposure and nor was the type of operation performed [ Table 6 ].
Results

Discussion
Vedolizumab, a biological agent that selectively inhibits leukocyte migration into the intestinal tract, has been shown to be an effective medical therapy for IBD. However, some have speculated that this mechanism of action may affect postoperative healing. In this single-centre retrospective cohort, we found that 53% of IBD patients who received vedolizumab within 12 weeks of a major abdominal operation had a postoperative complication, and 37% had a postoperative SSI, significantly higher [p<0.001] than the rate in patients exposed to TNFα inhibitors or no biological therapy. On multivariable regression analysis, patients who received vedolizumab were found to be four times as likely to experience an SSI as compared to the TNFα inhibitors or no biological therapy cohorts.
Most of the literature regarding infectious and anastomotic complications associated with perioperative biological therapy has focused on the use of infliximab within 12 weeks prior to surgery. While the literature remains controversial as to whether infliximab increases the risk of postoperative complications, a recent set of meta-analyses concluded infliximab does increase the rate of postoperative complications, especially postoperative infectious complications, which are reported to occur at a rate of 15-17%. [10] [11] [12] To date, there is no study published regarding the postoperative infectious complications in the setting of preoperative vedolizumab administration. In our study, we demonstrated that the rate of all postoperative complications, superficial SSIs, deep space SSIs and mucocutaneous separation were all significantly increased as compared to the TNFα inhibitor or no biological therapy control cohorts, and on multivariate analysis the exposure to vedolizumab remained a significant predictor for SSIs. These results underline the risk of postoperative infectious complications in the setting of preoperative vedolizumab exposure.
There are several limitations to this study. First, this is a singlecentre retrospective review performed at a large referral centre. These patients were referred on a variety of medical regimens, or with severe uncontrolled disease, implying this cohort may be a sicker cohort than patients treated elsewhere. In fact, many of the patients initially treated with vedolizumab were patients with medically refractory disease awaiting its FDA approval. Moreover, more than half of our patient cohort was on concomitant corticosteroid and/or immunomodulator therapy at the time of their abdominal operation. Secondly, because vedolizumab was only recently approved by the FDA in 2014, our study includes just 20 months of data, thereby limiting the number of patients included in our analysis. Third, only 12 patients in our series had a primary anastomosis without proximal diversion. Thus, we cannot adequately address the important question of anastomotic leak rate in the setting of perioperative administration of vedolizumab.
To better understand the role of vedolizumab on SSIs and anastomotic leak rate, it will be important to study postoperative complications in a prospective manner. This could be more readily accomplished by performing a multi-institution case control study. Additionally, it will be important to investigate if vedolizumab is associated with increased anastomotic leak rates, especially given its mechanism of blocking leukocyte migration to the intestine, a step critical for anastomotic healing. In conclusion, vedolizumab is an effective treatment for moderate to severe CD and UC, offering an attractive alternative to anti-TNFα therapy. As its use increases, it is expected that more patients referred to surgery will be receiving vedolizumab therapy. We found a 37% 30-day SSI rate and 53% postoperative complication rate in patients receiving vedolizumab in the perioperative period, a rate significantly higher than that seen in patients treated with TNFα inhibitors. Given the single-centre nature of this study, larger prospective studies would be useful to further define the impact of vedolizumab on postoperative SSIs and anastomotic leak rates. In the meantime, an active dialogue between treating gastroenterologists and colorectal surgeons is critical to optimize patient care and determine optimal operative timing, operative approach and need for diversion to protect anastomoses. 
